NASDAQ:ENLV   ENLIVEX THERAPEUTICS LTD
Sepsis is currently the number three cause of death in the Western world, after heart-lung failure and cancer. This is a market of more than $ 30 billion.
The Enlv product was originally intended for the treatment of sepsis (sepsis) and is in 2nd place in drug trials. The drug developed by Enlv is supposed to over-activate the immune system in patients with infectious diseases whose condition is severe. In severe situations the immune system can lose control and get into a spin known as a cytokine storm and cause extensive damage to the body. Enlv has decided to expand product development in corona treatment as well, after it became clear that this virus could, in severe cases, cause a cytokine storm.

Comments

Home Stock Screener Forex Screener Crypto Screener Economic Calendar How It Works Chart Features Pricing Refer a friend House Rules Help Center Website & Broker Solutions Widgets Charting Solutions Lightweight Charting Library Blog & News Twitter
Profile Profile Settings Account and Billing Referred friends Coins My Support Tickets Help Center Private Messages Chat Sign Out